Tsantan Sumtang Alleviates Chronic Hypoxia-Induced Pulmonary Hypertension by Inhibiting Proliferation of Pulmonary Vascular Cells.
BioMed Research International
Short Title:
BioMed Research International
Format:
Journal Article
Publication Date:
2018/11/28/
Pages:
1 - 13
Sources ID:
93496
Notes:
Accession Number: 133249081; He, Qilian 1,2,3 Nan, Xingmei 1,2 Li, Silin 4 Su, Shanshan 5 Ma, Ke 1,2 Li, Zhanqiang 1,2 Lu, Dianxiang 1,2 Ge, Rili 1,2; Affiliation: 1: Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China 2: Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province, Xining 810001, China 3: Medical Department, Medical College, Qinghai University, Xining 810001, China 4: Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Ha’erbin 150040, China 5: Qinghai Entry-Exit Inspection and Quarantine Bureau, Xining 810003, China; Source Info: 11/28/2018, p1; Subject Term: CELL proliferation; Subject Term: ANIMAL experimentation; Subject Term: HYPOXEMIA; Subject Term: BLOOD pressure; Subject Term: CELLULAR signal transduction; Subject Term: GENE expression; Subject Term: MUSCLE proteins; Subject Term: NITRIC oxide; Subject Term: NORADRENALINE; Subject Term: PROSTAGLANDINS; Subject Term: PROTEIN kinases; Subject Term: PULMONARY artery; Subject Term: PULMONARY hypertension; Subject Term: RATS; Subject Term: TRADITIONAL medicine; Subject Term: VASOCONSTRICTION; Subject Term: NUCLEAR proteins; Subject Term: IN vitro studies; Subject Term: RIGHT ventricular hypertrophy; Subject Term: PULMONARY arterial remodeling; Subject Term: IN vivo studies; Subject Term: DISEASE complications; Subject Term: TIBET (China); NAICS/Industry Codes: 112990 All Other Animal Production; Number of Pages: 13p; Document Type: Article; Full Text Word Count: 8426Accession Number: 133249081; He, Qilian 1,2,3 Nan, Xingmei 1,2 Li, Silin 4 Su, Shanshan 5 Ma, Ke 1,2 Li, Zhanqiang 1,2 Lu, Dianxiang 1,2 Ge, Rili 1,2; Affiliation: 1: Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China 2: Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province, Xining 810001, China 3: Medical Department, Medical College, Qinghai University, Xining 810001, China 4: Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Ha’erbin 150040, China 5: Qinghai Entry-Exit Inspection and Quarantine Bureau, Xining 810003, China; Source Info: 11/28/2018, p1; Subject Term: CELL proliferation; Subject Term: ANIMAL experimentation; Subject Term: HYPOXEMIA; Subject Term: BLOOD pressure; Subject Term: CELLULAR signal transduction; Subject Term: GENE expression; Subject Term: MUSCLE proteins; Subject Term: NITRIC oxide; Subject Term: NORADRENALINE; Subject Term: PROSTAGLANDINS; Subject Term: PROTEIN kinases; Subject Term: PULMONARY artery; Subject Term: PULMONARY hypertension; Subject Term: RATS; Subject Term: TRADITIONAL medicine; Subject Term: VASOCONSTRICTION; Subject Term: NUCLEAR proteins; Subject Term: IN vitro studies; Subject Term: RIGHT ventricular hypertrophy; Subject Term: PULMONARY arterial remodeling; Subject Term: IN vivo studies; Subject Term: DISEASE complications; Subject Term: TIBET (China); NAICS/Industry Codes: 112990 All Other Animal Production; Number of Pages: 13p; Document Type: Article; Full Text Word Count: 8426Accession Number: 133249081; He, Qilian 1,2,3 Nan, Xingmei 1,2 Li, Silin 4 Su, Shanshan 5 Ma, Ke 1,2 Li, Zhanqiang 1,2 Lu, Dianxiang 1,2 Ge, Rili 1,2; Affiliation: 1: Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China 2: Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province, Xining 810001, China 3: Medical Department, Medical College, Qinghai University, Xining 810001, China 4: Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Ha’erbin 150040, China 5: Qinghai Entry-Exit Inspection and Quarantine Bureau, Xining 810003, China; Source Info: 11/28/2018, p1; Subject Term: CELL proliferation; Subject Term: ANIMAL experimentation; Subject Term: HYPOXEMIA; Subject Term: BLOOD pressure; Subject Term: CELLULAR signal transduction; Subject Term: GENE expression; Subject Term: MUSCLE proteins; Subject Term: NITRIC oxide; Subject Term: NORADRENALINE; Subject Term: PROSTAGLANDINS; Subject Term: PROTEIN kinases; Subject Term: PULMONARY artery; Subject Term: PULMONARY hypertension; Subject Term: RATS; Subject Term: TRADITIONAL medicine; Subject Term: VASOCONSTRICTION; Subject Term: NUCLEAR proteins; Subject Term: IN vitro studies; Subject Term: RIGHT ventricular hypertrophy; Subject Term: PULMONARY arterial remodeling; Subject Term: IN vivo studies; Subject Term: DISEASE complications; Subject Term: TIBET (China); NAICS/Industry Codes: 112990 All Other Animal Production; Number of Pages: 13p; Document Type: Article; Full Text Word Count: 8426
Collection:
Himalayan and Tibetan Medicine
Visibility:
Public (group default)
Abstract:
(Show)
Hypoxia-induced pulmonary hypertension (HPH) is a severe condition associated with significant morbidity and mortality in people living at high altitude. Tsantan Sumtang, a traditional Tibetan medicine, has been routinely used for the treatment of cardiopyretic disease, as well as stenocardia. Interestingly, our previous research found that Tsantan Sumtang improved HPH in rats maintaining in a hypobaric chamber. We performed a series of experiments to test the indexes of vasoconstriction and vascular remodeling, the key pathophysiological characteristics of HPH. Our results showed that Tsantan Sumtang relaxed noradrenaline (NE)-precontracted rat pulmonary artery rings in a concentration-dependent manner in vitro. The PGI2-cAMP (prostaglandin I2-cyclic adenosine monophosphate) pathway, NO-cGMP (nitric oxide-cyclic guanosine monophosphate) pathway, and the opening of K+ channels (inward rectifier K+ channels, large conductance Ca2+-activated K+ channels, and voltage-dependent K+ channels) might play major roles in the vasorelaxation effect. In vivo, the administration of Tsantan Sumtang resulted in a substantial decrease in the rat mean pulmonary artery pressure (mPAP) and the right ventricular hypertrophy index (RVHI). The reduction of thickness of small pulmonary arterial wall and the WT% (the ratio of the vascular wall thickness to the vascular diameter) were observed. The smooth muscle muscularization of the arterials was alleviated by Tsantan Sumtang treatment at the same time. Tsantan Sumtang also reduced remodeling of pulmonary arterioles by suppressing the expression of proliferating cell nuclear antigen (PCNA), α-smooth muscle actin (α-SMA), cyclin D1, and cyclin-dependent kinase 4 (CDK4) through inhibition of p27Kip1 degradation. Therefore, Tsantan Sumtang could be applied as a preventative medication for HPH, which would be a new use for this traditional medicine. [ABSTRACT FROM AUTHOR]